Efforts to improve reporting clinical trial results have led to the development of guidelines such as those recommended by the CONSORT group. 3,4 Transparent and comprehensive reporting of subgroup ...
The MarketWatch News Department was not involved in the creation of this content.-- Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was ...
An analysis of reports from phase III trials (published between 2011 and 2013) investigating patients with solid tumours found widespread failings in both the conduct and reporting of subgroup ...
One of the most recognized features of No Child Left Behind is subgroup analysis, which shifted attention from the average performance of a school to the performance of specific populations within a ...
In oncology drug development, using biomarkers to select a study population more likely to benefit from a therapeutic effect is critical to increase the efficiency of a clinical trial in demonstrating ...
We conducted subanalyses of the combined results of the Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 studies to better ...
We evaluated the efficacy of raltegravir and the development of viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1 (HIV-1) with ...
The values of the subgroup-variable, which is specified in the chart statement, indicate how the observations in the input data set (a DATA=, HISTORY=, or TABLE= data set) are arranged into rational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results